What if the real obstacle in 3D cell culture and tissue engineering isn't the cells, but the very ground they grow on?

For years, cell culture has relied on flat plastic and passive scaffolds. But biology doesn't happen on a petri dish—cells live in three dimensions, surrounded by a dynamic environment that talks back, adapts, and shapes development in ways static gels simply cannot.

That's the premise behind MosaMatrix, a novel hydrogel platform designed to transform how we grow cells, engineer tissues, and screen new drugs created by CEO Jan Hunik and CTO Matt Baker.

Topics discussed:

• Why traditional flat, 2D cell culture misses the biological mark and what a responsive cell environment really looks like (00:27)
• The origins of MosaMatrix and the realization that new, adaptive hydrogels were needed for dynamic cell culture (04:45)
• What makes the MosaMatrix hydrogel different—and why passive scaffolds fall short (06:12)
• Mechanical and biological characteristics that define hydrogel performance, from stiffness to stress relaxation (07:48)
• The company's pivot from 3D tissue printing to focusing on high-throughput 3D cell culture for drug discovery (08:42)
• Advantages of a non-animal-derived, reproducible matrix for research and industry (10:20)
• Strategies for obtaining real-world customer feedback and working in consortia with academia and industry partners (11:51)
• Key hurdles in quality control, reproducibility, and measuring success in the emerging field (16:05)
• Challenges with standardizing organoids and the move to smaller, more automatable culture systems (17:50)
• The impact of automation and data consistency for scaling up 3D cell culture (18:14)

Smart insight: MosaMatrix validates its hydrogel not through internal R&D alone, but through direct collaboration with academic and industry partners — testing performance across cell types and culture media. This includes a ~50-company consortium building next-gen 3D cell culture tools and a new consortium improving kidney dialysis with living human cells. The partnerships surface real variables, like how much culture media composition affects results, that continually shape product development.

If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.

• Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
• Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
• Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch
• Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang

Connect with Jan Hunik and Matt Baker:

• Emails: matt.baker@mosamatrix.com and jan.hunik@mosamatrix.com
• Website: www.mosamatrix.com
• LinkedIn Jan Hunik: www.linkedin.com/in/jan-hunik-0183734
• LinkedIn Matt Baker: www.linkedin.com/in/matthew-baker-0abb981b

Support the show